IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科
学科主题临床医学
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
Fu, Zhiying; Zhu, Jun; Zheng, Wen; Liu, Weiping; Ying, Zhitao; Xie, Yan; Wang, Xiaopei; Lin, Ningjing; Tu, Meifeng; Ping, Lingyan; Deng, Lijuan; Zhang, Chen; Ding, Ning; Song, Yuqin
关键词Bevacizumab DLBCL Safety Efficacy
刊名CANCER CELL INTERNATIONAL
2014-01-18
DOI10.1186/1475-2867-14-5
14
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]CARDIOVASCULAR TOXICITY ; CANCER-PATIENTS ; RITUXIMAB ; TRIAL ; CHEMOTHERAPY ; METAANALYSIS ; MECHANISMS ; THERAPY ; RISK
英文摘要

Background: Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% - 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed that bevacizumab might be useful in the treatment of DLBCL. This study evaluated the safety and efficacy of bevacizumab combined with the R-CHOP (A-R-CHOP) regimen in Chinese patients with previously untreated DLBCL.

Methods: Patients with previously untreated DLBCL received A-R-CHOP regimen therapy. All patients with complete response (CR)/unconfirmed complete response(CRu) after 8 cycles of A-R-CHOP received the bevacizumab maintenance therapy once every 3 weeks. The remained bulky disease was treated with radiotherapy.

Results: Seven Chinese patients were treated. All of them had bulky diseases. One patient had progressive disease after 4 cycles of A-R-CHOP therapy. The rest six patients completed 8 cycles of A-R-CHOP treatment. All of these six patients reached CR/CRu (5 CR, 1 CRu). Bevacizumab maintenance therapy was given to 4 CR patients. All 7 patients experienced Grade 3/4 hematologic adverse events; additionally, one had Grade 3 gastrointestinal toxicity and one had Grade 1 epistaxis. During bevacizumab maintenance therapy, one patient had Grade 1 gingival bleeding, another experienced Grade 1 proteinuria and then Grade 3 congestive heart failure 4 months after completion of maintenance therapy. At the end of July 2013, the patient who had progressive disease after 4 cycles of A-R-CHOP died of progressive disease, the other six remained CR response.

Conclusions: The A-R-CHOP regimen is effective for untreated DLBCL, but may cause bevacizumab-specific toxicities, which should be monitored.

语种英语
WOS记录号WOS:000334613500001
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61794
专题北京大学临床肿瘤学院_淋巴肿瘤内科
作者单位Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Fu, Zhiying,Zhu, Jun,Zheng, Wen,et al. Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma[J]. CANCER CELL INTERNATIONAL,2014,14.
APA Fu, Zhiying.,Zhu, Jun.,Zheng, Wen.,Liu, Weiping.,Ying, Zhitao.,...&Song, Yuqin.(2014).Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma.CANCER CELL INTERNATIONAL,14.
MLA Fu, Zhiying,et al."Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma".CANCER CELL INTERNATIONAL 14(2014).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Fu, Zhiying]的文章
[Zhu, Jun]的文章
[Zheng, Wen]的文章
百度学术
百度学术中相似的文章
[Fu, Zhiying]的文章
[Zhu, Jun]的文章
[Zheng, Wen]的文章
必应学术
必应学术中相似的文章
[Fu, Zhiying]的文章
[Zhu, Jun]的文章
[Zheng, Wen]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。